Dr. Sachs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
15 Parkman St
Wac 8
Boston, MA 02114Phone+1 617-724-6544Fax+1 617-726-6768
Education & Training
- Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1983 - 1986
- University of Maryland/Sheppard PrattResidency, Psychiatry, 1982 - 1982
- University of Maryland School of MedicineClass of 1982
Certifications & Licensure
- CA State Medical License 1988 - Present
- MA State Medical License 1984 - 2025
- FL State Medical License 2019 - 2021
- MD State Medical License 1983 - 1983
- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Start of enrollment: 1998 Sep 01
- A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression Start of enrollment: 2008 Nov 01
Publications & Presentations
PubMed
- 93 citationsSleep Functioning in Relation to Mood, Function, and Quality of Life at Entry to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)June Gruber, Allison G. Harvey, Po W. Wang, John O. Brooks, Michael E. Thase
Journal of Affective Disorders. 2009-04-01 - 84 citationsPersonality and bipolar disorder: dissecting state and trait associations between mood and personality.Jennifer H. Barnett, Jinyan Huang, Roy H. Perlis, M M Young, Jerrold F. Rosenbaum
Psychological Medicine. 2011-08-01 - 528 citationsWhole-genome association study of bipolar disorderPamela Sklar, Jordan W. Smoller, Jinbo Fan, Manuel A. R. Ferreira, Roy H. Perlis
Molecular Psychiatry. 2008-06-01
Press Mentions
- U.S. FDA Approves VRAYLAR® (Cariprazine) as an Adjunctive Treatment for Major Depressive DisorderDecember 17th, 2022
- Antipsychotic Safe, Effective for Resistant Depression in Phase 3 TrialMay 26th, 2022
- Add-on Vraylar Tied to Easing of Recurrent Depressive SymptomsMay 22nd, 2022
- Join now to see all
Grant Support
- Pilot Study Of A Calcium Channel Blocker In FemalesNational Institute Of Mental Health1999–2000
- Treatment Of Bipolar DisorderNational Institute Of Mental Health1998–2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: